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1. Introduction 
Proliferation/survival, migration and invasion are processes common to both primary 
tumor angiogenesis and metastases formation. Among the treatment approaches being 
investigated, the most developed is the use of genomics and proteomics research to assist 
the identification of unique targets involved in tumor angiogenesis or invasiveness. In 
addition, metastasis in breast cancer patients accounts for over 90% of the deaths. Preclinical 
studies reveal that many drugs used in the management of primary tumors are not or little 
effective against metastasis (Perret & Crepin, 2008). Although the mechanism by which 
metastases develop is still not fully understood, it is generally believed that tumor cells 
acquire features that affect their metastatic potential during the progression of the tumor; 
these features include increased survival, invasive and migratory abilities of breast cancer 
cells. Breast cancer progression is a complex cascade of sequential steps, none of which 
being fully understood. Many studies implicated stroma in the development of metastases. 
Stroma and cancer cell interactions were found to contribute to cell detachment from 
primary tumors, intravasation into the blood stream, and extravasation at distant sites 
where tumor cells can seed and form tumor metastases (Shekhar et al., 2003). Previously, 
fibroblasts, endothelial cells and macrophages and other stroma cells were reported to be 
implicated in the occurrence of metastases (Cunha et al., 1992; Haslam et al., 2001; Shekhar 
et al., 2003). In these conditions, new strategies as well as the identification of novel 
therapeutic targets will be needed to effectively target the interactions between stroma and 
tumor cells via growth factor. Thus, it is important to take into account not also the context 
near tumor cells (like growth factors as well as chemokines) but also the distribution of the 
tumor cells in the metastatic sites.  
As of today, the poorly predictive preclinical models, lack of tumor target specificity, lack of 
effective cellular and intracellular delivery, development of resistance have slowed down 
the progress in anti-cancer therapy. Although the pharmaceutical industry prefers to 
develop small molecule therapy that can be orally administered to patients, it is now 
admitted that development of new drug delivery system strategy is essential to increase 
therapeutic index. Synthetic and natural polymers have an established role as in several 
biomedical applications, including their use as prosthesis or implants (Anderson, 2001). 
During the past decade, polymer implants have been used in cancer therapy to treat locally 
hormone-dependent tumors (Zoladex, Lupron depot) or brain tumors by implanting 
chemotherapy delivering polymer post-surgically. Over than 10 water-soluble polymer 
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drugs conjugates have entered in phase I/II clinical trials as I.V. administrated anticancer 
agents. These include six conjugates based on methacrylamide polymers (HPMA). These 
polymers have been developed in the basis of the achieved tumor–specific targeting by the 
enhanced permeability and retention effect (Ducan et al., 2005; Matsumura et al., 1986). This 
increasing tumor retention has been observed and attributed to the better extravasation in 
the blood vessel of macromolecules and the absence of their drainage release (Noguchi Y et 
al., 1998; Seymour et al., 1995). HPMA copolymer conjugate with chemotherapeutic agents 
as doxorubicin has shown high retention and efficacy toward tumors without side effects 
(Ducan et al., 2005). The specific tumor cell targeting can also be attributed to the interaction 
of copolymers and heparin growth factors which are highly expressed in the tumor cell 
environment. Better retention is also attributed to the endocytic internalisation of conjugates 
which allows also to bypassing MDR efflux responsible for drug resistance. Also, another 
type of natural polymer interesting to be evaluated is the glycoaminoglycans analogs since it 
is well-known that they importantly interact with growth factors and receptors on the cell 
membranes. In another hand, the different type of glycosaminoglycans on the cell surface 
support in relation with normal or tumoral statues supported their involvement. We have 
recently developed the two kinds of copolymers that show interesting results in basis of the 
possibility to functionalize them with active biomolecules. Among active biomolecules, the 
interesting ones are those which inhibited the ancrage of rho/ras signaling molecules to 
tumor cells since this pathway plays a key role in invasion, migration and proliferation of 
tumor cells. The inhibition of the prenylation of ras and rho leads to the blocking of ancrage 
to the membrane. We have focused our attention on two types of such small molecules. The 
first one, phenylacetate (NaPa), comes from the metabolism (Fig. 1). NaPa, which has been 
originally used for urea children disorders (Samid et al., 1992, 1993) has since been 
demonstrated to efficiently inhibits cancer cell lines proliferation in vitro. The second small 
molecules are bisphosphonates (PBs, fig 1), which are mostly known for their efficacy in the 
treatment of bone disorders and are also efficient in vitro in inhibiting cancer cell 
proliferation. For both molecules, the main obstacle with their use in cancer therapy stems  
 
                  
Fig. 1. Phenylacetate (NaPa) and bisphosphonates (BPs) molecules. 
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from the high concentrations (up to micromolars) that are needed to achieve efficacy in vivo. 
Since we think that these molecules remain of potential use in cancer because they target 
specific step involved in both primary tumor growth and metastasis formation, we are 
developing new strategies that aim to increase their efficacy using drug delivery systems in 
specific cancer cells localized in specific sites. Herein, we will present all these strategies, 
first by using polymers for NaPa, and secondly using chemical transformation of the 
compounds, in particular esterification for the bisphosphonates. Also we will present 
possible future directions, such as the use of new polymers as well as new delivery systems 
like nanotechnologies. 
2. Glycoaminoglycan polymer strategy 
2.1 Carboxybenzylamide dextran (CMDB) and NaPa combination 
Carboxymethyl benzylamide dextran derivative (in particular CMDB7) inhibits breast cancer 
cell proliferation in vitro and in nude mice (Bagheri-Yarmand et al, 1992, 1997, 1998a, b, 1999). 
This in vitro effect is associated with a decrease in the S-phase cell population and with an 
accumulation of cells in G1 phase of cell cycle (Bagheri-Yarmand et al, 1992). CMDB7 
disrupts the mitogenic effect of growth factors by preventing their binding to specific 
receptors as reported for Fibroblast Growth Factor-2 and -4 (FGF2, FGF4, Bagheri-Yarmand et 
al, 1998a), Platelet-Derived Growth Factor-BB and Transforming Growth Factor-ǃ1 (PDGF-
BB, TGFΒ Bagheri-Yarmand et al, 1998b). In vivo, CMDB7 treatment reduces the growth of 
MCF-7ras (Bagheri-Yarmand et al, 1998b) and FGF4-transfected HBL100 xenografts and 
decreases the tumor angiogenesis (Bagheri-Yarmand et al, 1998a). Sodium phenylacetate 
(NaPa), a physiological metabolite of phenylalanine, is normally found in human plasma at 
micromolar concentrations. At higher concentrations, NaPa is reported to induce the 
cytostasis and the reversion of malignant phenotype of different cancer cells in vitro (Samid et 
al, 1993, 1994, 1997, 2000; Adam et al, 1995). Furthermore, NaPa is described to modulate the 
synthesis and/or the release of some growth factors (Ferrandina et al, 1997; Thibout et al, 
1998) and to increase, in synergistic manner, the effect of some molecules affecting the growth 
factor pathways (Prasanna et al, 1996; Samid et al, 1993). For example, NaPa potentiates the 
antitumor activity of tamoxifen by increasing apoptosis in breast cancer xenografts in nude 
mice. Finally, NaPa has been used in phase I and II clinical trials on patients with malignant 
tumors (Chang et al., 1999; Thibault et al, 1994). In basis of this data, we have evaluated in 
vitro and in vivo the efficacy of combined treatment with NaPa and an industrial dextran 
derivative LS4 (Sterilyo Laboratories) whose composition is similar to CMDB7 one, on breast 
cancer cell growth. We have used the MCF-7ras cell line obtained by transfection of MCF-7 
cells, isolated from pleural metastasis of breast adenocarcinoma, with v-Ha-ras oncogene. The 
MCF-7ras cells secrete high quantities of TGFǂ, TGFǃ, epithelial growth factor (EGF) and 
insulin growth factor (IGF) (Albini et al, 1986). This cell line represents an oestrogen-
independent cellular model corresponding to some malignant breast tumors (Spandidos and 
Agnantis, 1984) and does no require oestrogen supplementation to induce a high incidence of 
tumors in nude mice (Sommers et al, 1990). The analysis of CMDBLS4-NaPa combination 
effect is performed by the isobole method.  
NaPa enhances the dextran derivative CMDBLS4 antiproliferative effect on breast cancer 
MCF-7ras cells both in vitro and in vivo. Indeed, NaPa or CMDBLS4, delivered alone for 7 
weeks, inhibits MCF-7ras tumor growth by 60% and 40%, respectively, while the CMDBLS4-
NaPa combination decreases MCF-7ras tumor growth by 83% without any toxicity. The 
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effectiveness of the NaPa and CMDBLS4 combination can be explained by their distinct 
mechanisms of action. MCF-7ras breast cancer cells secrete an important amount of mitogenic 
growth factors such as TGFǃ and PDGF (Bronzert et al, 1987; Dickson et al, 1987; Knabbe et 
al, 1987). The mitogenic effects of these growth factors can be reduced by inhibition of their 
synthesis or/and their action on target cells. Treatment of cells with NaPa decreases the 
mitogenic activity of MCF-7ras conditioned medium on BALBc/3T3. The possible 
mechanism is a modulation of the synthesis and the release of growth factors like TGFǃ in 
MCF-7ras breast cancer cells (Thibout et al, 1998). CMDBLS4, when added to conditioned 
medium, inhibits conditioned medium mitogenic effect on BALBc/3T3 fibroblasts. This 
finding argues for CMDBLS4 interactions with growth factors contained in CM. Indeed, 
previous studies have shown that dextran derivatives interact with heparin-binding growth 
factors like TGFǃ, PDGFBB or FGF-2 and inhibit their mitogenic effect (Bagheri-Yarmand et 
al, 1998a, b). All our and others’ observations suggest that NaPa and CMDBLS4 act on 
distinct targets involved in the tumor development. NaPa alters the mitogenic growth factor 
production and renders the tumor cells quiescent in the G1 phase while CMDBLS4 interacts 
with MCF-7ras growth factors and inhibits their mitogenic activities. 
 
aCMDBLS4  NaPa % I CMDBLS4 NaPa D  
(Ac; mM)  (Bc; mM)  (Ae; mM) (Be; mM)  
48 h       
3.7  0.75 33 18.5 17 0.44b  
7.4  1.5 45.8 >18.5 30 0.45b  
14.8  3 48.1 >18.5 32.1 0.89  
18.5  4 50 >18.5 34 1.12  
72 h       
3.7  0.75 51.4 >18.5 20.6 0.23b  
7.4  1.5 54.8 >18.5 23 0.46b  
14.8  3 53.3 >18.5 24 0.93  
18.5  4 60.2 >18.5 29 1.13  
Table 1. Effects of NaPa and CMDBLS4 combination with a ratio = 5 on MCF-7ras cell 
proliferation. a Ac and Bc, concentrations of agents A and B used in the combination 
treatment; Ae and Be,concentrations of agents A and B able to produce the same magnitude 
of effect if used individually. D combination index If D=1 the effect is additive, id D<1, the 
effect is synergistic.b P < 0.05. % of inhibition determined by MTT assay:[1–(absorbance of 
cells in medium containing agents/absorbance of cells in control culture medium)]× 100.(Di 
Benedetto et al., 2001). 
2.2 Carboxybenzylamide –phenylacetate dextran (NaPaC) 
NaPa molecule enhances, in a synergistic or additive manner, the inhibitory effect of CMDB 
on breast cancer cell growth in vitro and in nude mice when administrated at a 
CMDB/NaPa ratio of 4 (Di Benedetto et al., 2001). To obtain a new drug with the same 
properties but easier to use as a future anti-cancer molecule than the combined treatment, 
we have performed the esterification of CMDB by NaPa respecting the synergistic 
CMDB/NaPa ratio. We have then investigated the in vitro and in vivo effects of this new 
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dextran derivative, phenylacetate carboxymethyl benzylamide dextran, named NaPaC, on 
breast cancer cell proliferation as well as its apoptotic and anti-angiogenic effects. 
 
 
Fig. 2. Carboxymethylbenzylamide-NaPa (NaPac) (A) and heparin (B) molecules (Di 
Benedetto et al., 2002). 
Interestingly, NaPaC inhibits the growth of breast cancer MCF-7ras cells at a concentration 
lower than CMDB or NaPa. The comparison of IC50 for three drugs supplies the additional 
evidence for the highly enhanced efficiency of NaPaC as compared to CMDB and NaPa 
(Table 2). Therefore, the hybrid molecule retains at least the additive effect of its two 
components observed previously (Di Benedetto et al., 2001). This effect is not only specifc to 
MCF-7 ras cells as similar results are obtained for other breast cancer cell lines, including 
MCF-7, MDA-MB-231 and MDA-MB-435. NaPaC inhibited in vivo MCF-7ras tumor growth 
more efficiently and at lower dose than CMDB or NaPa. This can be explained by the fact 
that NaPaC gathers the antiproliferative, aponecrotic and anti-angiogenic actions generally 
admitted to lead in vivo to concerted inhibition of tumor growth. The inhibition of the 
endothelium growth, causing the impaired delivery of nutrients and oxygen to tumor, leads 
to tumor cell death. Indeed, we observed in vivo that the inhibition of MCF-7ras tumor 
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
400 
growth by NaPaC is concomitant with a poor microvessel density (as compared to control) 
at short-time treatment and with multifocal necrotic areas at long-term administration. 
Therefore, NaPaC is more efficient than CMDB or NaPa and decreases the microvessel 
density at dose lower than its components.  
 
Treatment 
Tumor (volume) at 
Day 1 (mm3) 
Tumor (volume) at 
day 5(mm3) 
Tumour 
growth (%) 
Control  221+90 2103+328 - 
NaP4 40 m/ kg (0.25 mmol/ kg) 157+30 990+192 57 
CMDB 150 mg/kg (1.85 µmol/kg)  199+70 1326+281 33 
NaPaC 15 m/kg (0.18 mmol/ kg)  167+40 717+203 66 
Table 2. Inhibition of MCF-7ras tumor growth by NaPaC and its components, CMDB and 
NaPa. MCF-7ras cells were inoculated s.c in nude mice near the fad pad. After tumor 
uptake, the animals were treated for 7 weeks with NaPa (n=10), CMDB (n=10) and NaPaC 
(n=10). Tumor volume (+s.e.m.) for different experimental groups were compared to control 
(Di Benedetto et al., 2002). 
Of note, no necrotic areas were detected in tumors treated with CMDB or NaPa alone. In 
accord with our in vivo results on tumor neovascularization, NaPaC in vitro inhibits the 
growth of human endothelial cells more efficiently that CMDB or NaPa. The mechanisms 
involved in CMDB and NaPa actions on endothelial cell proliferation seem to be distinct. 
CMDB interacts directly with VEGF165 (Hamma-Kourbali et al., 2001), the most specific 
angiogenic factor (Plouet et al., 1989) and inhibits the VEGF165-induced HUVE-C-C growth.  
 
 
Fig. 3. Inhibition of MCF-7ras tumor angiogenesis by NaPaC, CMDB and NaPa. Microvessel 
staining of tumors untreated (A) and treated with 150 mg/kg CMDB (B), 40 mg/kg NaPa 
(C) or 15 mg/kg NaPaC (D), twice a week, for 7 weeks, was performed using GSL-1 lectin. 
Necrotic areas in panel d are indicated with the asterisks. Magnification X250 was used for 
panels A,B and C, and magnification X100 was applied for panel D. The representative 
microvessels in panels A±C are marked with the arrows (Di Benedetto et al., 2002). 
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In our laboratory, we observe that NaPa do not interact with VEGF 165 molecule, and has 
no effect on VEGF165-dependent cell growth. Up to date, the mechanism of NaPa action on 
HUVE-C-C growth is unknown. Concerning NaPaC, it inherits the CMDB ability to interact 
with angiogenic growth factor and blocks the VEGF165-induced endothelial cell 
proliferation at lower concentration than CMDB (Fig. 4). However, the involvement of the 
NaPa mechanism in NaPaC action on HUVE-C-C growth is still unknown. 
 
 
Fig. 4. NaPaC directly interacts with VEGF165. After a 1 h incubation of 125I-VEGF165 (105 
c.p.m.=3 ng) with NaPaC or NaPa at 48C, the mixtures (10 ml) were electrophoretically 
analysed in non denaturant 1% agarose gel at pH 7.0. Lane 1 represents the migration of 
125I-VEGF165 alone; lanes 2 ± 6 correspond to 0.6, 1.8, 5.5, 15 or 48 mM NaPaC; lanes 7 ± 10 
represent the shifts after addition of 1.0, 5.0, 10 or 20 mM NaPa (Di Benedetto et al., 2003). 
Finally, it is noteworthy that NaPa treatments at high concentrations can induce 
pathological effects (Thibault et al., 1994; Chang et al., 1999). The use of non-toxic new 
molecule, NaPaC, should limit side effects of NaPa and increase its therapeutic efficacy. In 
conclusion, NaPaC provides additional interesting clues in developing new anti-cancer 
drugs with specific triple activity: antiproliferative, aponecrotic and anti-angiogenic. The 
inhibition of angiogenesis is crucial for blocking tumor progression since tumor-associated 
high-density neovascularization is responsible for development of metastases.  
3. Bisphosphonate esterifications 
Bisphosphonates (BPs) have long been used in metabolic bone disease as osteoporosis, 
tumor-associated hypercalcaemia and metastases-induced osteolysis due to their ability to 
inhibit bone resorption. BPs are able to bind divalent cations like Ca2+ or zinc, constituting 
the basis of their bone-targeting property and their inhibition of the proteolytic activity of 
matrix metalloproteinases (MMP), respectively. The nature of their side chains gives rise to a 
variety of possible structures and stereochemistry determining their different potencies 
(Clezardin et al., 2005; Cleardin et al., 2003; Caraglia et al., 2006; Green, 2003). Non-nitrogen 
containing BPs (non N-BPs) act by forming non hydrolysable ATP-analogues and are less 
effective than nitrogen-containing BPs (N-BPs) in inhibiting bone metastasis (Roger et al., 
2003). However, Zoledronate treatment of patients are reported to induce toxic side effect 
characterised by osteonecrosis of the jaw while non N-BP did not produce this effect (Van 
den Wingaert, 2006; Diel et al., 2007). N-BPs, such as zoledronate, act on the mevalonate 
pathway, inhibiting the farnesyl diphosphate synthase (FPP) and thereby depleting the cells 
of the farnesyl (FPP) or geranylgeranyl (GGPP) diphosphate isoprenoids (Roelofs et al., 
2006). Isoprenoids are required for translocation and anchorage of small G proteins like Rho 
or Ras to the plasma membrane assuring their ultimate involvement in signal transduction 
during several important normal and tumor cellular pathways. However, in vivo efficacy of 
all BPs on extra-osseous sites or primary tumors is still debated. Only a small number of 
studies have demonstrated their in vivo antiproliferative activity on tumors or metastasis  
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present in soft tissues (Stresing et al., 2007). The reasons are the poor oral bioavaibility (0.3-
7% in humans) due to chelation of metal ions by phosphonic acid group inside the digestive 
lumen, poor membrane permeability due to poor BP lipophilicity as well as strong uptake 
by bone tissue (Ezra & Colomb, 2000). Previously, new strategy to overcome BP 
hydrophilicity is masking the phosphonic acid with organic protecting groups and 
introducing hydrophobic functions in the side chain (Migianu et al., 2005). An esterified BP 
with methyl group displays antitumor growth and antiangiogenic activities on A431 
tumors, being more effective in vivo than in vitro (Ledoux et al., 2006). In order to further 
increase the lipophilicity of BPs (and their entering into the cells), we have synthesized new 
aromatic 1-hydroxymethylene-1,1-bisphosphonic acids containing phenyl or halogen phenyl 
ring in their side chains. Interestingly, these compounds exhibit potent antiproliferative 
activities in vitro on human epidermoid A431 cells (Guenin et al., 2005). In parallel, recently 
crystallographic and computational investigation reveal that the presence of phenyl ring in 
the side chain permitted non N-BPs to interact with farnesyl enzyme (Mao et al., 2006). 
Based on these data, we have synthesized a class of BPs that contains bromobenzyl in their 
side chains (BP7033Br, Fig. 5), as well assymmetrically esterified one of each phosphonic 
acids with aromatic groups (BP7033Br ALK, Fig. 5).  
 
 
Fig. 5. Chemical structure of BP7033Br and BP7033Br ALK (Abdelkarim et al., 2009). 
BPs represents an emerging class of drugs for cancer therapy and new class of non-N-BPs 
which exhibits higher antiproliferative activities on breast cancer cells compared to 
previously described non-N-BPs such as clodronate (Journe et al., 2004). Both types of m-
bromobenzyl BPs inhibit the viability of several breast cancer cell lines with different 
estrogen-receptor statuses (Fig. 6). The esterified BP is the more effective on estrogen-
responsive cells since the maximal inhibition is reached at 250 µM in contrast to non 
esterified BP that does not induce maximal inhibition even at 1 mM. In addition, at 250 µM, 
BP7033Br ALK is effective on cells independently from the estrogen-receptor status. Both 
types of our BP inhibits viability of estrogen non-responsive cells and particularly that of 
MDA-MB-231 and D3H2LN cells, the last cell line being the more aggressive ones. Indeed, it 
is worth to note that dramatic improvement of antiproliferative effect of non-N-BPs on 
breast cancer cells is reached since clodronate at the same concentration range (200 µM) and 
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the same time-treatment (72h) do not reduce MDA-MB-231 cell viability (Fromigue et al., 
2000; Monkkonene et al., 2008; Senaratne et al., 2000). In addition, clodronate demonstrates 
mitogenic effects via MCF7 estrogenic receptor (Journe et al., 2004) and we never observe 
this effect with our BPs. Based on our results, it appears also that BP7033Br ALK 
antiproliferative effect is estrogen-receptor-independent. The occurrence of this new effect of 
non-N-BPs could result from the addition of aromatic functions in the side chain. 
Heterocycle in the side chain is implicated in the induction of cell apoptosis by preventing 
the prenylation of signalling proteins such as Ras or Rho (Luckman et al., 1998). Inhibition of 
Ras processing using non bromo-containing BP7033 is also reached (Hamma-kourbali et al., 
2003). Also, the addition of phenyl function in the side chain of BPs rendered the catalytic 
pocket of geranyl and/or farnesyl synthase enzymes of the mevalonate pathway more 
accessible (Mao et al., 2006; Steeg et al., 2006). BP7033Br ALK reduces MDA-MB-231 and 
D3H2LN cell viabilities about 90% with a concentration 4-fold inferior to that of BP7033Br.  
 
 
Fig. 6. BP7033Br and BP7033Br ALK inhibited viability of different breast cancer cells. T47D 
(A), MCF-7 (B), SKBR3 (C), MDA-MB-231 (D) or D3H2LN cells (E) (1x105) were treated with 
BP7033Br and BP7033Br ALK at increasing concentrations for 72h. Then, the cells were 
washed and incubated with 0.1 mL of MTT (2 mg/mL) for 4 h. Optical density was 
measured at 570 nm using a Labsystems Multiskan MS microplate reader. Data represents 
the mean value (± SD) of three independent experiments (Abdelkarim et al., 2009). 
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These data are in agreement with previous results on epidermoid A431 cell proliferation 
that show a beneficial effect of esterification of the phosphonic groups (Guenin et al., 2005; 
Ledoux et al., 2006). Our hypothesis is that such esterified compounds rendered BPs more 
hydrophobic increasing their cell uptake and could therefore act like prodrugs releasing 
active BP into the cells. In accordance, characterisation of the hydrophilicity demonstrated a 
shift toward lipophilicity of the BP7033Br ALK compound (Log P values of -0.75 versus -031, 
respectively). Alternatively, one could also hypothesize that esterified BPs have their own 
mechanisms since they block the cells into the S phase while non esterified BPs inhibits the 
G0/G1 cell phase transition. On the other hand, both type of BPs (esterified or not) induce 
cell death apoptosis of both MDA-MB-231 and D3H2LN cells. These results are interesting 
since D3H2LN cells have a greater metastatic potential than MDA-MB-231 and consequently 
could be more resistant to apoptosis, as it is described for metastatic cells (Wang et al., 2002; 
Winter et al., 2008). Both BPs induce strong D3H2LN metastatic cell apoptosis but the 
concentration of the esterified analogue used is 2-fold lower. Also, the two BPs inhibits 
migration of MDA-MB-231 cell lines with a more important effect obtained with BP7033Br 
ALK. In contrast, BP7033Br ALK is less effective in inhibiting D3H2LN cell lines invasion 
concomitant with a less important effect on MMP-9 and MMP-2 activities. BP7033Br 
strongly inhibits MMP-9 and MMP-2, the major form of metalloproteinases present in 
extracellular matrix. Since MMPs are zinc-dependent endopeptidases, we speculate that the 
reduction of BP7033Br ALK effect could be due to a reduction of available phosphonic acid 
groups able to chelate zinc and consequently inhibit MMPs. These results are in agreement 
with previous studies which show that MMPs inhibition activity by BPs is related to zinc 
chelation (Clezardin et al., 2003). However, we hypothesise that release of BP7033Br ALK 
with free phosphonic group could be more important in in vivo system because of the 
presence of phosphodiesterases in serum. 
BPs antitumor effects have been mainly observed on D3H2LN xenografts growth and 
metastasis (Fig. 7). D3H2LN cells have been derived from a MDA-MB-231 subclone isolated 
from a lymph node metastases and induce an increased xenograft tumor growth as 
compared to parental cells when injected in vivo (Jenkins et al., 2005). Both BP7033Br and 
BP7033Br ALK inhibit D3H2LN tumor growth after intratumoral injection of about 286 µg 
BPs per mouse twice a week during 21 days. We establish that this new class of BPs is the 
most potent among the current non N-BPs since clodronate, even used at 1600 mg twice 
daily during several weeks (as compared to BP7033 ALK corresponding human dose of 770 
mg twice a week during only 2 weeks) fails to reduce primary tumor growth (Winter et al., 
2008). Also, BPs are 10-fold more potent than the non halogenated phenyl analogues 
(Sebbah-Louriki et al., 2002). In addition, BP7033Br ALK better inhibits D3H2LN vessel 
density than BP7033Br. This point is also supported by the large necrosis area not detected 
in BP7033Br treated tumors. In addition, we cannot exclude that these large necrosis areas 
could also be due to a greater amount of esterified BP penetrating into tumor to induce cell 
death. As compared to N-BPs, it is noteworthy that risedronate or ibandronate failed to 
inhibit MDA-MB-231 tumor growth in nude mice (Higara et al., 2001, Sasaki et al., 1995). 
Furthermore, no pre-clinical works demonstrate an antiproliferative effect of zoledronate  
on primary breast tumor growth in nude mice. The only study demonstrating an  
inhibition effect of zoledronate on primary tumor growth uses mesothelioma tumors which 
involves calcification that could uptake the drug (Wakchoure et al., 2006) In addition, the 
efficacy of zoledronate on bone metastasis seems to be supported by its affinity for osseous 
tissues rather than its direct antiproliferative effect on tumor cells (Winter et al., 2008).  
 
www.intechopen.com
 
New Experimental Therapies Targetting Breast Cancer Cell 
 
405 
Fig. 7. Only BP7033Br ALK inhibited D3H2LN metastasis. D3H2LN cells were injected into 
the left ventricle of nude mice (n=7). Day 0 showed the successful intracardiac cells injection. 
Within 2 weeks, when metastasis were initiated, mice were treated with BP7033Br ALK or 
BP7033Br (A). At the indicated days, the bioluminescence images were acquired for control 
(c, left panel) and BPs treated mice (BP7033BrALK and BP7033Br middle and right panel, 
respectively). Ex vivo data confirm soft tissue metastasis from D3H2LN cells injection (B). 
Quantification of the mean metastatic sites and the photons/s after BP7033Br ALK treatment 
(C). Quantification the photons/s after BP7033Br treatment (D). Each column represents a 
mean (±SD) of three independent experiments. *Pversus control < 0.05 (Abdelkarim et al., 2009). 
Also, zoledronate is a compound rapidly eliminated from plasma, resulting in renal 
excretion, rapid bone or calcified tissues uptake and accumulation partly due to its 
phosphonic functions. We have recently showed that the symmetrical esterification of the 
phosphonic groups may improved BPs soft tissue bioavaibility limiting osseous or calcified 
tissue uptake (Ref). Also, as their chemical structures are close to the apomine BP, which 
presents aliphatic ester group, their half-life are expected to be close to that found for this 
drug (156 h with micromolar plasma concentration, (Alberts et al., 2001). Thus, esterified 
BP7033Br ALK abrogates angiogenesis, both soft tissue and bone metastasis whereas 
BP7033Br does not. Noteworthy, in BP7033Br treated mice, luminescence signalling of leg 
osseous metastasis is not significantly reduced because 2/7 mice do not respond to the 
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treatment in contrast to BP7033Br ALK treatment that induces significant reduction (Ref). 
Indeed, the esterified functions seem to be important for the BPs distribution within the 
systemic system and less for local injection (subcutaneous tumors) since the two N-BPs 
studied both inhibit D3H2LN xenograft growth. Of note, N-BPs induced osteonecrosis of 
treated patients (Diel et al., 2007) whereas no apparent side effects have been observed with 
non N-BPs. Therefore, esterified m-bromobenzyl non N-BPs constitute a new class of drugs 
with potent direct antitumor, antiangiogenic and antimetastatic efficacy on breast tumors 
(Abdelkarim et al., 2009). 
4. Future directions Polynass/nanotechnologies 
4.1 PolyNASS polymers 
Polymers display antiproliferative, aponecrotic and anti-angiogenic effects without 
cytotoxicity on endothelial and cancer cells. Indeed, after 4 days of incubation, only 0,6µM of 
20MA/80NaSS is required to induce 85% of cell growth inhibition of MDA-MB-231 cell 
growth. In contrast and interestingly, in HUVECs cells, polymers 50MA/50NaSS is more 
efficient with 70% inhibition achieved with 0,06µM (Fig. 8). The effect of 20MA/80NaSS on 
breast tumor cell is not specific only to MDA-MB-231 cells since it also inhibits other breast 
cancer cell lines MCF-7 (Skhiri et al., 2008).The inhibition achieved with MA/NaSS polymers 
is comparable to that obtained in non invasive breast carcinoma cell MCF-7 (Skhiri et al., 
2008)and the inhibition effect varies in function of percentage of carboxylate and sufonate 
content in polymers. Interestingly, the strongly percentage of tumor cell proliferation 
inhibition was observed in presence of 20MA/80NaSS polymer. At 6µM, this polymer 
induces up to 80% of inhibition of the cellular MDA-MB-231cancer cell proliferation after 4 
days of culture. On the other hand, at the same concentration, the polyNaSS effect on 
cellular proliferation was much lower (60%). Indeed, the presence of two groupings 
carboxylate and sufonate is necessary and plays an important role in breast cancer anti-
proliferation inhibition activity. Also, it seems that similar proportion (50 MA/50 NASS) of 
functional subunits is rather an interesting chemical composition to obtain the optimal 
inhibition of endothelial cells proliferation. In addition, it seems that a strong proportion of 
sulfonate units in polymers is necessary for a high antiproliferative activity in cancer cells 
while the equal proportion of the functional groups are necessary for the endothelial cells. 
These results suggest that the mechanism implicated in the inhibition of the two types of 
cells is different. The effect of these two copolymers on HUVEC and MDA-MB231 cell cycle 
was also different as a decrease of cells in the S-phase and an accumulation of cells in 
G0/G1-phase were observed. In conclusion, these new type of polymers could lead to the 
development of new anti-cancer drugs with specific triple activity: antiproliferative, 
aponecrotic and anti-angiogenic. Since the development of resistant tumor cell clones can be 
a serious problem, the inhibition of angiogenesis is crucial for blocking tumour progression 
since tumor associated high density neovascularization is responsible for development of 
metastases. Therefore, polymers could be good candidate by selectively inhibiting tumor 
cells or endothelial cells in basis of their composition. 
In addition, these kinds of molecule could be conjugated with specific drugs (copolymers) 
that will target genes specific to endothelial or tumors cell activities enhancing in this way, 
the benefit of the therapies. It is to note that in contrast to glycoaminoglycan like polymers, 
PolyNASS polymer synthesis is better controlled in basis of their chemical composition that 
is determined by titration of carboxylic groups and 1H NMR. 
www.intechopen.com
 
New Experimental Therapies Targetting Breast Cancer Cell 
 
407 
 
 
 
Fig. 8. Stucture-function relationship of PolyNASS copolymers and penetration into MDA-
MB-231 tumor (left) and HUVEC endothelial cells (right). 
4.2 Nanotechnologies 
An innovative multimodal system, which combines magnetic targeting of therapeutic agents 
with both magnetic resonance and fluorescence imaging into one system has been recently 
described (Bennayou et al., 2011). This new magnetic nanoplatform consists of 
superparamagnetic ǄFe2O3 nanoparticles, used clinically as an MRI contrast agent, 
conjugated to therapeutic molecules of the hydroxylmethylene bisphosphonate family 
(HMBPs): alendronate with an amine function as the terminal group. In vitro tests with 
breast cancer cells show that the ǄFe2O3@alendronate hybrid nanomaterial reduces cell 
viability and acts as a drug delivery system. The presence of both ǄFe2O3@alendronate and a 
magnetic field significantly reduced the development of tumors. The amine functionalities 
can be used as precursor groups for the covalent coupling of peptides or monoclonal 
antibodies for specific biological targeting. The feasibility of this process is demonstrated by 
coupling rhodamine B, a fluorescence marker, to the ǄFe2O3@alendronate nanohybrid. The 
system shows fluorescent properties and high affinity for cells. Therefore, magnetic and 
fluorescent nanoparticles are potential candidates for smart drug-delivery systems. Also, the 
superparamagnetic behaviour of such nanoparticles may be exploited as MRI contrast 
agents to improve therapeutic diagnostics. 
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Fig. 9. Nanoplatform showing the possibility to graft BPs on superparamagnetic ǄFe2O3 
nanoparticles. 
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